Psychological effects of ketamine in healthy volunteers: Phenomenological study

Department of Psychiatry, University of Cambridge, Cambridge, England, United Kingdom
The British Journal of Psychiatry (Impact Factor: 7.99). 09/2006; 189(2):173-9. DOI: 10.1192/bjp.bp.105.015263
Source: PubMed


The psychosis-inducing effect of ketamine is important evidence supporting the glutamate hypothesis of schizophrenia. However, the symptoms the drug produces have not been described systematically.
To examine the effects of ketamine in healthy people using a structured psychiatric interview.
Ketamine (200 ng/ml) or placebo was administered by continuous infusion to 15 healthy volunteers. Symptoms were rated using the Present State Examination, the Thought, Language and Communication Scale and the Scale for Assessment of Negative Symptoms.
Ketamine induced a range of perceptual distortions, but not hallucinations. Referential ideas were seen in nearly half the sample. There were only mild and infrequent ratings on the thought disorder scale. Affective flattening and alogia were seen in some volunteers.
Ketamine does not reproduce the full picture of schizophrenia. The main point of similarity concerns referential thinking. Phenomena resembling negative symptoms are also seen, but the distinction of these from the drug's sedative effects requires further elucidation.

Download full-text


Available from: Garry Honey, Nov 18, 2014
  • Source
    • "Clinician-Administered Dissociative States Scale (CADSS) (Pomarol-Clotet et al., 2006; Zarate et al., 2012; Luckenbaugh et al., 2014). In the study by Luckenbaugh et al. (2014), the maximum increases in CADSS scores were observed at the end of a 40 min infusion of (R,S)-ketamine (0.5 mg·kg −1 ), which was followed by a rapid decline to below baseline at the 80 min sampling point. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with major depressive disorder receiving racemic ketamine, (R,S)-ketamine, experience transient increases in Clinician-Administered Dissociative States Scale (CADDS) scores and coincident drop in plasma D-serine levels. The results suggest that (R,S)-ketamine produces an immediate, concentration-dependent pharmacological effect on D-serine plasma concentrations. One potential source of this effect is the (R,S)-ketamine-induced inhibition of the alanine-serine-cysteine transporter (ASCT2), which regulates intracellular D-serine concentrations. In this study, we have tested this hypothesis by examining the effect of (S)- and (R)-ketamine on the ASCT2-mediated transport of D-serine in PC-12 and 1321N1 cells and primary neuronal cells in culture. Intracellular and extracellular D-serine levels were determined using capillary electrophoresis-laser induced fluorescence and liquid chromatography-mass spectrometry, respectively. Expression of ASCT2, Asc-1 and serine racemase was determined utilizing western blotting. Incubation with (S)-ketamine produced a concentration-dependent increase in intracellular D-serine levels and reduced extracellular D-serine accumulation. In contrast, (R)-ketamine decreased both the intracellular and extracellular D-serine levels. The contribution of ASCT2 and Asc-1 in ketamine-mediated D-serine transport was then assessed. Both the pharmacological inhibition of ASCT2 with benzyl-D-serine and ASCT2 gene knockdown mimicked the action of (S)-ketamine toward D-serine levels in PC-12 cells, while incubation with the Asc-1 agonist D-isoleucine reduced intracellular D-serine levels and increased extracellular D-serine accumulation. This response to D-isoleucine was not affected by benzyl-D-serine or (S)-ketamine. Primary cultures of rat neuronal cells expressed ASCT2 and were responsive to (S)-ketamine and benzyl-D-serine. Incubation with (S)-ketamine and (R)-ketamine increased the expression of monomeric serine racemase in all the studied cells, with (S)-ketamine having the greatest effect. The results indicate that (S)-ketamine decreases cellular export of D-serine via selective inhibition of ASCT2, and this could represent a possible source of dissociative effects observed with (R,S)-ketamine. This article is protected by copyright. All rights reserved.
    Full-text · Article · Jul 2015 · British Journal of Pharmacology
    • "Together these findings indicate NMDAR autoantibodies might play a causal role in some cases of psychosis. An association between NMDAR antibody and schizophrenia is biologically plausible; NMDAR blockade with ketamine produces psychotic symptoms in healthy volunteers (Pomarol-Clotet et al. 2006). Since a variety of infections, atopic disorders and autoimmune conditions are associated with schizophrenia, it is possible that they share a common underlying pathway most likely involving the inflammatory immune response. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Schizophrenia is characterised by hallucinations, delusions, depression-like so-called negative symptoms, cognitive dysfunction, impaired neurodevelopment and neurodegeneration. Epidemiological and genetic studies strongly indicate a role of inflammation and immunity in the pathogenesis of symptoms of schizophrenia. Evidence accrued over the last two decades has demonstrated that there are a number of pathways through which systemic inflammation can exert profound influence on the brain leading to changes in mood, cognition and behaviour. The peripheral immune system-to-brain communication pathways have been studied extensively in the context of depression where inflammatory cytokines are thought to play a key role. In this review, we highlight novel evidence suggesting an important role of peripheral immune-to-brain communication pathways in schizophrenia. We discuss recent population-based longitudinal studies that report an association between elevated levels of circulating inflammatory cytokines and subsequent risk of psychosis. We discuss emerging evidence indicating potentially important role of blood-brain barrier endothelial cells in peripheral immune-to-brain communication, which may be also relevant for schizophrenia. Drawing on clinical and preclinical studies, we discuss whether immune-mediated mechanisms could help to explain some of the clinical and pathophysiological features of schizophrenia. We discuss implication of these findings for approaches to diagnosis, treatment and research in future. Finally, pointing towards links with early-life adversity, we consider whether persistent low-grade activation of the innate immune response, as a result of impaired foetal or childhood development, could be a common mechanism underlying the high comorbidity between certain neuropsychiatric and physical illnesses, such as schizophrenia, depression, heart disease and type-two diabetes.
    No preview · Article · Jun 2015 · Psychopharmacology
  • Source
    • "The commonest feature was referential thinking of a delusional nature, together with a range of perceptual abnormalities perhaps best described as dissociative. However, it did not induce hallucinations, and the authors were doubtful about its ability to cause thought disorder; furthermore, although negative-like symptoms resulted they could not exclude the possibility that this was simply due to its anesthetic effects [Pomarol-Clotet et al., 2006]. In a similar vein, Morgan and Curran [2012] who reviewed the literature, noted that ketamine users sometimes reported psychotic symptoms but concluded that " there is little evidence of any link between chronic heavy use of ketamine and a diagnosis of a psychotic disorder. "
    [Show abstract] [Hide abstract]
    ABSTRACT: When drug-induced psychoses were first identified in the mid-20th century, schizophrenia was considered a discrete disease with a likely genetic cause. Consequently, drug-induced psychoses were not considered central to understanding schizophrenia as they were thought to be phenocopies rather than examples of the illness secondary to a particular known cause. However, now that we know that schizophrenia is a clinical syndrome with multiple component causes, then it is clear that the drug-induced psychoses have much to teach us. This article shows how the major neuropharmacological theories of schizophrenia have their origins in studies of the effects of drugs of abuse. Research into the effects of LSD initiated the serotonergic model; amphetamines the dopamine hypothesis, PCP and ketamine the glutamatergic hypothesis, while most recently the effects of cannabis have provoked interest in the role of endocannabinoids in schizophrenia. None of these models account for the complete picture of schizophrenia; rather the various drug models mimic different aspects of the illness. Determining the different molecular effects of those drugs whose pharmacological effects do and do not mimic the various aspects of schizophrenia has much to teach us concerning the pathogenesis of the illness. © 2013 Wiley Periodicals, Inc.
    Full-text · Article · Oct 2013 · American Journal of Medical Genetics Part B Neuropsychiatric Genetics
Show more